N-Desethyl Protonitazene: Metabolite, Standalone Nitazene, Toxicology & Safety Monograph

N-Desethyl Protonitazene: Metabolite, Standalone Nitazene, Toxicology & Safety Monograph

Emergency opioid warning: If someone cannot be awakened, has slow, irregular, or stopped breathing, blue/gray lips or skin, gurgling/choking sounds, or collapses after an unknown opioid, powder, pill, or vape, call emergency services and give naloxone if available. Do not wait for exact nitazene identification.

Quick answer

N-desethyl protonitazene (NDP) is both a metabolite of protonitazene and an emerging nitazene drug that has been found as a standalone ingredient in illicit drug material.

That dual identity is the most important fact on this page.

If NDP appears in a biological specimen, there are at least two possibilities:

1. the person used protonitazene, which the body converted partly to N-desethyl protonitazene; or
2. the person was exposed directly to N-desethyl protonitazene as a drug.

Those possibilities cannot be distinguished from the NDP result alone.

The direct evidence base is still uneven:

• chemical identity: established;
• MOR agonism: established in vitro;
• protonitazene-metabolite role: established in authentic human urine;
• standalone drug-market presence: established analytically;
• standalone human overdose series: not established;
• controlled human PK: not established;
• NDP-specific withdrawal timeline: not established.

Identity

History: first a metabolite, then a drug-market substance

N-desethyl protonitazene first became scientifically important as part of the metabolism of protonitazene.

A 2024 study used human liver microsomes and authentic urine from two fatal protonitazene intoxications and identified N-desethyl protonitazene among the major metabolites.

Then the evidence changed.

CFSRE reported first confirming N-desethyl protonitazene as a drug in its own right in November 2024.

The submitted drug material:

• originated from Chicago;
• appeared as yellow powder;
• contained N-desethyl protonitazene;
• also contained fentanyl and adulterants such as diphenhydramine and quinine.

That finding shows the molecule is not merely a metabolic biomarker anymore.

Pharmacology

Mu-opioid receptor agonism

CFSRE's 2025 monograph summarizes receptor data showing N-desethyl protonitazene acts as a potent mu-opioid receptor agonist.

In the cited assay:

• N-desethyl protonitazene EC50: 10.1 nM;
• fentanyl: 25.7 nM;
• protonitazene: 1.57 nM;
• N-desethyl isotonitazene: 0.317 nM.

What those numbers mean

They show that NDP was highly potent in that experimental receptor system.

They do not establish:

• a human fentanyl-equivalent dose;
• a safe exposure;
• a lethal dose;
• a reliable conversion from protonitazene.

Different receptor assays can generate different relative-potency ratios.

The defensible conclusion is simply:

N-desethyl protonitazene is a high-potency MOR agonist with pharmacology consistent with serious opioid-overdose risk.

The metabolite problem: why toxicology interpretation is unusually tricky

A 2024 human-metabolism study found N-desethyl protonitazene in authentic urine from two fatal protonitazene intoxications.

The metabolite-to-parent ratios were greater than 1 in those urine samples.

That makes NDP a potentially useful marker for extending the detection window of protonitazene exposure.

But once NDP also became a standalone drug, interpretation became more complicated.

Finding NDP can mean different things

A biological specimen containing NDP could reflect:

• direct NDP exposure;
• protonitazene metabolism;
• both;
• a mixed illicit product.

What strengthens evidence for direct NDP use?

Potentially useful contextual clues include:

• NDP detected in drug material associated with the case;
• absence/presence and relative concentration of protonitazene;
• metabolite pattern;
• scene evidence;
• updated analytical knowledge.

Even then, attribution should be cautious.

Human clinical evidence

Standalone human toxicity is still sparse

At the time of CFSRE's June 2025 monograph, the laboratory reported that it had not detected N-desethyl protonitazene in toxicology cases without protonitazene.

That is a major evidence boundary.

The drug had been confirmed in standalone drug material, but the published human toxicology record had not yet clearly separated direct NDP exposure from metabolism of protonitazene.

Therefore this article does not invent an NDP-specific clinical syndrome.

Acute toxicity and overdose

Although standalone clinical data are sparse, NDP's MOR pharmacology creates a credible opioid-toxicity risk.

Expected severe opioid effects include:

• profound sedation;
• pinpoint pupils;
• slow or stopped breathing;
• hypoxia;
• aspiration;
• unresponsiveness;
• bradycardia/hypotension;
• cardiac arrest;
• death.

The exact exposure needed to produce those effects in humans is unknown.

Naloxone

Naloxone is appropriate when an opioid overdose is suspected, regardless of whether the specific opioid is known.

There is no NDP-specific clinical trial establishing:

• a special naloxone dose;
• a guaranteed number of doses;
• a specific observation period.

Potent nitazenes can require repeated emergency treatment, and co-drugs can complicate recovery.

Interactions and polysubstance risk

The first confirmed standalone NDP drug material also contained fentanyl.

That is highly relevant.

Real-world NDP exposure may occur in a polysubstance supply rather than as a purified single compound.

Highest concern involves:

• fentanyl or other opioids;
• benzodiazepines;
• alcohol;
• xylazine-containing mixtures;
• gabapentinoids;
• other sedative-hypnotics.

The primary danger is compounded CNS and respiratory depression.

Tolerance

Repeated exposure to potent MOR agonists can produce opioid tolerance.

No prospective NDP-specific human study defines:

• how quickly tolerance develops;
• cross-tolerance with fentanyl or other nitazenes;
• whether tolerance to subjective effects parallels tolerance to respiratory depression.

Tolerance should never be treated as protection against overdose.

Physical dependence

Repeated potent opioid exposure can produce physical dependence.

For NDP specifically, incidence is unknown because direct standalone human-use cohorts do not exist.

The most accurate statement is:

Physical dependence is strongly class-supported and pharmacologically plausible, but NDP-specific frequency and timeline are not quantified.

Withdrawal

No validated NDP-specific withdrawal timeline exists.

If physical dependence develops, opioid-type withdrawal may include:

• restlessness;
• sweating/chills;
• insomnia;
• nausea, vomiting, or diarrhea;
• abdominal cramps;
• muscle aches;
• anxiety;
• autonomic activation;
• craving.

A self-directed taper cannot be derived responsibly from the current literature.

Dependence vs opioid use disorder

Physical dependence and opioid use disorder are related but distinct.

Physical dependence means withdrawal occurs after neuroadaptation.

Opioid use disorder involves a broader pattern such as:

• craving;
• inability to cut down;
• compulsive use;
• continued use despite harm;
• repeated hazardous use;
• interference with work or relationships.

A person can become dependent on an opioid-contaminated supply without knowing which nitazene is present.

Treatment and support

There is no NDP-specific addiction-treatment protocol.

Clinicians can evaluate opioid withdrawal and opioid use disorder using established opioid-care frameworks.

Evidence-based medications for OUD include:

• buprenorphine;
• methadone;
• extended-release naltrexone in appropriate patients after sufficient opioid abstinence.

This page does not provide self-induction or taper dosing.

U.S. resources:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Emergency overdose, severe dehydration, pregnancy with significant withdrawal, severe confusion, chest pain, or suicidal thoughts require urgent medical evaluation.

Metabolism

Formation from protonitazene

NDP forms through N-deethylation of protonitazene.

The 2024 metabolism study also identified other protonitazene metabolites, including:

• 5-amino-protonitazene;
• hydroxy-related metabolites.

The authors concluded that testing for metabolites can improve the detection window of protonitazene exposure.

Standalone NDP metabolism

A complete human metabolic map after direct NDP administration has not been established.

This is another example where evidence from protonitazene metabolism should not be overextended.

Pharmacokinetics

There is no controlled human NDP pharmacokinetic study establishing:

• oral or other-route bioavailability;
• time to peak;
• half-life;
• volume of distribution;
• clearance;
• accumulation;
• active metabolites.

A metabolite detected after protonitazene exposure does not establish NDP's standalone PK.

Drug testing and analytical toxicology

Routine screening

Routine opioid or fentanyl immunoassays should not be assumed to identify NDP.

A negative fentanyl screen does not rule out a nitazene.

Definitive methods

Identification may require:

• LC-MS/MS;
• LC-QTOF-MS;
• LC-HRMS;
• authentic reference material;
• parent/metabolite contextual interpretation.

CFSRE confirmed the drug material using GC-MS and LC-QTOF-MS against reference material.

Forensic interpretation

This is one of the most important sections for NDP.

Detection does not prove direct administration

Because NDP is a protonitazene metabolite:

NDP in urine or blood does not automatically mean a person intentionally used NDP.

Parent-metabolite relationships matter

Interpretation should consider:

• protonitazene concentration;
• NDP concentration;
• other protonitazene metabolites;
• specimen type;
• timing;
• product evidence.

Standalone drug evidence changes the question

Before November 2024, NDP could reasonably be approached primarily as a metabolite.

After standalone drug-material confirmation, direct exposure became a real alternative explanation.

No universal fatal concentration

There is no validated NDP-specific fatal blood concentration.

A concentration observed in a protonitazene fatality may reflect metabolism rather than a directly ingested NDP dose.

Counterfeit and product-identity risk

NDP's first confirmed standalone material was not a clean pharmaceutical product.

It appeared with:

• fentanyl;
• diphenhydramine;
• quinine.

That demonstrates a central NPS harm-reduction problem:

Chemical identity and co-exposure cannot be inferred from a street name, seller description, or expected drug class.

Special populations

No controlled NDP-specific studies establish safety in:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• sleep apnea/COPD;
• liver or kidney disease;
• people using multiple sedatives.

For a potent opioid with unknown human PK, missing evidence increases uncertainty rather than indicating safety.

Legal status — verified for October 2, 2026

United States

CFSRE's June 2025 monograph correctly stated that NDP was not yet federally scheduled at that time.

That statement is now outdated.

DEA temporarily placed N-desethyl protonitazene and six other benzimidazole opioids in Schedule I effective October 15, 2025.

The temporary order runs through October 15, 2027, unless extended or superseded by permanent scheduling.

International

UNODC tracks N-desethyl protonitazene as a synthetic opioid/nitazene.

Do not confuse it with N-desethyl isotonitazene, which has a separate international scheduling history.

This review does not treat international control of one N-desethyl nitazene as proof of identical control for another.

Myths and misconceptions

“N-desethyl protonitazene is only a metabolite, not a drug.”
Outdated. It has been analytically confirmed in standalone drug material.

“Finding NDP proves direct NDP use.”
False. It can arise from protonitazene metabolism.

“It is exactly X times stronger than fentanyl in people.”
No. The in-vitro EC50 comparison is not a human dose conversion.

“A negative fentanyl test rules it out.”
False.

“No standalone overdose series means it is safe.”
False. It means the direct human evidence remains sparse.

“The 2025 CFSRE page says it is unscheduled, so that is still current.”
No. DEA's temporary Schedule I order took effect October 15, 2025.

Evidence ledger

Related evidence

• Nitazene opioid family
• Protonitazene
• N-Pyrrolidino Protonitazene / Protonitazepyne
• Isotonitazene
• Metonitazene
• Substance Use, Dependence & Harm Reduction hub

Bottom line

N-desethyl protonitazene is scientifically unusual because it occupies two roles at once.

It is an important metabolite that can help laboratories recognize protonitazene exposure—and it is now also a confirmed standalone opioid in the illicit drug supply.

That means toxicology interpretation has to answer more than “was NDP present?”

It has to ask why it was present.

That distinction is the difference between a shallow drug page and a useful forensic/harm-reduction reference.